Thymidylate synthase pharmacogenetics
- 26 October 2005
- journal article
- review article
- Published by Springer Nature in Investigational New Drugs
- Vol. 23 (6) , 533-537
- https://doi.org/10.1007/s10637-005-4021-7
Abstract
Thymidylate synthase (TYMS) is an important target for chemotherapy drugs, such as 5-fluorouracil (5FU) and methotrexate. Over-expression of TYMS is linked to resistance to TYMS-targeted chemotherapy drugs. Currently there is no protocol for selecting cancer patients at risk for drug resistance prior to chemotherapy treatment. Three polymorphisms in the 5′ and 3′ untranslated regions (5′UTR and 3′UTR) of the thymidylate synthase gene have been shown to influence TYMS expression. Preliminary data has suggested a poorer response rate to 5FU or methotrexate is seen in patients with 3 copies of a 28 bp tandem repeat in the 5′UTR enhancer region (TSER polymorphism) and this relationship may be further clarified by the presence of a single nucleotide polymorphism (SNP) with the second repeat of the 3 repeat (TSER *3) allele. A 6 bp deletion in the 3′UTR of the TYMS gene has also been shown to affect TYMS RNA expression and has a significant association with poor outcome in 5FU treated patients. Evidence linking all 3 TYMS polymorphisms with TYMS expression and patient response to TYMS-targeted chemotherapy treatment will be highlighted.Keywords
This publication has 32 references indexed in Scilit:
- Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene.2003
- Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer.2003
- The influence of cyclin D1 (CCND1) 870A>G polymorphism and CCND1-thymidylate synthase (TS) gene???gene interaction on the outcome of childhood acute lymphoblastic leukaemiaPharmacogenetics, 2003
- Pharmacogenomics — Drug Disposition, Drug Targets, and Side EffectsNew England Journal of Medicine, 2003
- Thymidylate Synthase Pharmacogenetics in Colorectal CancerClinical Colorectal Cancer, 2001
- Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancerInternational Journal of Oncology, 2001
- Ethnic Variation in the Thymidylate Synthase Enhancer Region Polymorphism among Caucasian and Asian PopulationsGenomics, 1999
- Functional Analysis and DNA Polymorphism of the Tandemly Repeated Sequences in the 5'-terminal Regulatory Region of the Human Gene for Thymidylate Synthase.Cell Structure and Function, 1995
- Regulatory sequences clustered at the 5? end of the first intron of the human thymidylate synthase gene function in cooperation with the promoter regionSomatic Cell and Molecular Genetics, 1992
- Role in translation of a triple tandemly repeated sequence in the 5′-untranslated region of human thymidylate synthase mRNANucleic Acids Research, 1987